{"agency": "Health and Human Sevices", "agency_short": "HHS", "published": "2022-10-05T00:00:00", "title": "AO 22-19", "url": "https://oig.hhs.gov/compliance/advisory-opinions/22-19/", "attachments": [{"title": "Advisory Opinion 22-19", "url": "https://oig.hhs.gov/documents/advisory-opinions/1056/AO-22-19.pdf", "mimetype": "application/pdf"}], "classification": "advisory-opinion", "identifier": "HHS-OIG-AO-22-19", "subagency": "Office of the Inspector General", "summary": "Regarding a proposal whereby certain pharmaceutical manufacturers would: (i) fund, through Requestor, cost-sharing subsidies for the manufacturers\u2019 Part D oncology drugs; (ii) fund, through Requestor, specified programs and eligible beneficiaries\u2019 health insurance premiums; and (iii) finance Requestor\u2019s operating costs."}